Century Therapeutics (IPSC) Gains from Investment Securities (2020 - 2026)
Century Therapeutics (IPSC) reported Gains from Investment Securities of $5.2 million for Q1 2026, up 16290.62% year-over-year from N/an in Q1 2025, and up 25.62% on a QoQ basis from $4.2 million in Q4 2025.
Century Therapeutics (IPSC) has 7 years of Gains from Investment Securities data on file, last reported at $5.2 million in Q1 2026.
- Quarterly Gains from Investment Securities rose 16290.62% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 145.73% YoY) and the FY2025 annual result came in at $4.2 million, down 56.14% from the prior year.
- Gains from Investment Securities improved to $5.2 million in Q1 2026 per IPSC's latest filing, from $4.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $5.8 million in Q4 2022 and bottomed at -$84000.0 in Q4 2024.
- The 5-year median for Gains from Investment Securities is $1.1 million (2023), against an average of $2.0 million.
- The widest annual swing landed in 2024, when Gains from Investment Securities tumbled 107.92%; it then surged 16290.62% in 2026.
- Tracing IPSC's Gains from Investment Securities over 5 years: stood at $5.8 million in 2022, then tumbled by 81.66% to $1.1 million in 2023, then tumbled by 107.92% to -$84000.0 in 2024, then jumped by 5070.77% to $4.2 million in 2025, then grew by 25.62% to $5.2 million in 2026.
- Per Business Quant, the three latest IPSC Gains from Investment Securities figures stand at $5.2 million (Q1 2026), $4.2 million (Q4 2025), and $1.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Century Therapeutics | 474.01 Mn | 474.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | 4.18 Mn |
| Dec 31, 2025 | 4.18 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 4.26 Mn |
| Jun 30, 2025 | 4.26 Mn |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | -84,000.00 |
| Dec 31, 2024 | -84,000.00 |
| Sep 30, 2024 | 659,020.00 |
| Sep 30, 2024 | 659,020.00 |
| Jun 30, 2024 | 505,154.00 |
| Jun 30, 2024 | 505,154.00 |
| Mar 31, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 1.06 Mn |
| Dec 31, 2023 | 1.06 Mn |
| Sep 30, 2023 | 4.61 Mn |
| Sep 30, 2023 | 4.61 Mn |
| Jun 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 2.44 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Sep 30, 2022 | 169,326.00 |
| Sep 30, 2022 | 169,326.00 |
| Jun 30, 2022 | 56,160.00 |
| Jun 30, 2022 | 56,160.00 |
| Mar 31, 2022 | 40,120.00 |
| Mar 31, 2022 | 40,120.00 |
| Dec 31, 2021 | 213,624.00 |
| Dec 31, 2021 | 213,624.00 |
| Sep 30, 2021 | 194,320.00 |
| Sep 30, 2021 | 194,320.00 |
| Jun 30, 2021 | 98,936.00 |
| Jun 30, 2021 | 98,936.00 |
| Dec 31, 2020 | 213,624.00 |
| Dec 31, 2020 | 213,624.00 |